Project Connexus was created to prevent diabetes, cardiovascular diseases and periodontitis, because they are serious diseases that are closely correlated to one another.
Type II Diabetes [T2D] and Periodontitis [PD] are amongst the most prevalent non-communicable (chronic inflammatory) diseases in the world. They compromise the quality of life of millions of people. Between 1980 and 2014, T2D global prevalence went from 110 Million to 420 Million. The projection for the next 20 years will be of 700 million people suffering from T2D.
A metanalysis from 2009 revealed that T2D patients had double the risk of developing PD compared to patients without T2D, and almost all patients with T2D suffered from PD too.
We all know that patients affected by T2D have metabolic hyperglycemia, and that, eventually, they will develop cardiovascular complications, diabetic retinopathy, neuropathy and nephropathy in the medium-long period.
These said complications should bring all medical categories that are involved in prevention to provide efficient protocols to reduce the incidence of this pathology.
The bidirectionality between Diabetic and Periodontal pathology is well documented in international literature: Diabetic Patients are highly susceptible to severe periodontitis, which increases the risk of developing chronic hyperglycemia.
The effects that Periodontitis has on diabetes are correlated to the penetration of mouth bacteria or their degradation products in the circulation. These events produce, through the increase in inflammatory chemical mediators, an increase in the systemic inflammation, which facilitates the incidence of insulin-resistance. The prolonged exposure to hyperglycemia leads to proteins and lipid glycation (AGE), a phenomenon that explains the typical microcirculation complications in T2D patients. We also know that the typical glycation in T2D patients is the same as HbA1c glycation.
The link between AGE and Monocyte Receptors causes the production of inflammatory cytokines IL-1, IL-6, TNF-alpha and PDGF, and the increase in inflammatory markers like CRP, which is an independent predictor of cardiovascular diseases.
Strong scientific evidences (especially systematic revisions with metanalysis) show that Periodontitis treatment improves glucose metabolic function, decreasing the levels of serum HbA1c and CRP, leading to the decrease of general inflammation.
The results show a 35% reduction of T2D-related cardiovascular complications for each HbA1 percentage point reduction.
The improvement in inflammation parameters in patients who suffer from T2D following Periodontitis therapy brings up important considerations on the necessity to include Periodontal treatment in the treatment of these patients; This will positively influence, to a great degree, the atero-cardio-vascular complications. A revision published in 2020 by Wu et al. on the epidemiologic relationship between T2D and PD has shown the following results:
Include, in the therapy of these patients, periodontal treatment that will positively affect especially the well-known athero-cardio-vascular complications
Strong scientific evidences on the bidirectional correlation between PD-T2D should:
Contact us via mail or via telephone to build a joint strategy.
We invite all physicians: Diabetologists, Cardiologists, Internists, General Practitioners